The use of hematopoietic stem cells in autoimmune diseases

Regen Med. 2016 Jun;11(4):395-405. doi: 10.2217/rme-2015-0057. Epub 2016 May 11.

Abstract

Hematopoietic stem cells (HSCs) have been shown recently to hold much promise in curing autoimmune diseases. Newly diagnosed Type 1 diabetes individuals have been successfully reverted to normoglycemia by administration of autologous HSCs in association with a nonmyeloablative regimen (antithymocyte globulin + cyclophasmide). Furthermore, recent trials reported positive results by using HSCs in treatment of systemic sclerosis, multiple sclerosis and rheumatoid arthritis as well. Early data suggested that HSCs possess immunological properties that may be harnessed to alleviate the symptoms of individuals with autoimmune disorders and possibly induce remission of autoimmune diseases. Mechanistically, HSCs may facilitate the generation of regulatory T cells, may inhibit the function of autoreactive T-cell function and may reshape the immune system.

Keywords: Type 1 diabetes; autoimmune diseases; hematopoietic stem cells.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / therapy*
  • Hematopoietic Stem Cell Transplantation / statistics & numerical data*
  • Humans